摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl (E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-3-methoxycarbonyl-2,3-dihydro-1-benzofuran-5-yl]prop-2-enoate

中文名称
——
中文别名
——
英文名称
methyl (E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-3-methoxycarbonyl-2,3-dihydro-1-benzofuran-5-yl]prop-2-enoate
英文别名
methyl 2-(3,4-dihydroxyphenyl)-7-hydroxy-5-[(E)-3-methoxy-3-oxoprop-1-enyl]-2,3-dihydro-1-benzofuran-3-carboxylate
methyl (E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-3-methoxycarbonyl-2,3-dihydro-1-benzofuran-5-yl]prop-2-enoate化学式
CAS
——
化学式
C20H18O8
mdl
——
分子量
386.358
InChiKey
HDONJQIYHGHIJV-ZZXKWVIFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    28
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    123
  • 氢给体数:
    3
  • 氢受体数:
    8

反应信息

  • 作为反应物:
    描述:
    methyl (E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-3-methoxycarbonyl-2,3-dihydro-1-benzofuran-5-yl]prop-2-enoateN-溴代丁二酰亚胺(NBS)乙酸乙酯 、 Brine 、 magnesium sulfate 作用下, 以 乙腈 为溶剂, 反应 3.0h, 以to give 15.94 g of the title compound的产率得到5-溴-2,3-二氢苯并呋喃
    参考文献:
    名称:
    Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it
    摘要:
    本发明提供了一种新型羧酸衍生物,可用作胰岛素敏化剂,其盐或水合物,以及包含该衍生物作为活性成分的药物。具体而言,提供了一种由以下式(I)表示的羧酸衍生物(其中Y、L、X、T、Z、U、M和W在规范中定义),其盐、酯或水合物。
    公开号:
    US07687664B2
  • 作为产物:
    描述:
    参考文献:
    名称:
    洋葱固体废物中的粗过氧化物酶可作为有机合成的工具。第II部分:的氧化二聚环化甲基p -coumarate,咖啡酸甲酯和甲基阿魏
    摘要:
    提出了一种粗洋葱过氧化物酶制剂作为对-香豆酸甲酯,咖啡酸甲酯和阿魏酸甲酯的氧化二聚化-环化反应的生物催化剂的能力。该反应的产物已得到充分表征,并在三氧化二铁还原性抗氧化剂能力(FRAP)分析中发现具有有效的抗氧化剂活性。
    DOI:
    10.1016/j.tetlet.2011.01.004
点击查看最新优质反应信息

文献信息

  • New Insights into the Acid-Promoted Reaction of Caffeic Acid and Its Esters with Nitrite:  Decarboxylation Drives Chain Nitrosation Pathways toward Novel Oxime Derivatives and Oxidation/Fragmentation Products Thereof
    作者:Alessandra Napolitano、Marco d'Ischia
    DOI:10.1021/jo015965v
    日期:2002.2.1
    methyl ester (1b) reacted with NO(2)(-) chiefly via ring nitration and/or dimerization to give 5a, the novel nitrated neolignan derivative 10, and the parent 6. Chlorogenic acid (1c) afforded only the ring nitrated derivative 5b. A unifying mechanism for the reaction of 1a and its esters with NO(2)(-) is proposed involving reversible formation of nitroso intermediates via chain nitrosation at the 2-position
    在含有1%甲醇的0.05 M醋酸盐缓冲液(pH 4)中,咖啡酸(1a)(2 x 10(-3)M)与亚硝酸盐(NO(2)(-))(4 x 10(-3)平稳反应M)作为主要产品提供较小的新型2-羟基-和2-甲氧基醛肟7a,b,2-环氧醛肟9a,3,4-二羟基苯甲酸,3,4-二羟基苯甲醛和已知的呋喃喃3c和苯并恶嗪酮4b金额。在较低的1a浓度下(例如1 x 10(-4)M),主要产物为7a,而0.1 m 1a和0.5 M NO(2)(-)3c和9a为主要产物。在pH 2时,7a与3,4-二羟基苯甲醛和一些9a仍然是最丰富的产物,而在pH 1时,9a和3,4-二羟基苯甲醛的产率更高。没有获得关于环硝化产物的证据,包括先前报道的4,5-二羟基-2-硝基苯甲醛。在2 x 10(-3)M浓度和pH 4下 咖啡酸甲酯(1b)主要通过环硝化和/或二聚反应与NO(2)(-)反应生成5a,新型硝化的新木脂素衍生
  • USE OF BENZOFURAN LIGNANS TO INDUCE IL-25 EXPRESSION AND SUPPRESS MAMMARY TUMOR METASTASIS
    申请人:Yang Ning-Sun
    公开号:US20200289454A1
    公开(公告)日:2020-09-17
    A method for suppressing tumor metastasis, in which an effective amount of a compound of formula (I) is administered to a subject in need thereof. Also disclosed is a method of treating cancer, in which an effective amount of a chemotherapy agent and an effective amount of a compound of formula (I) is administered to a subject in need thereof. Further disclosed are pharmaceutical compositions for suppressing tumor metastasis and for treating cancer, each of the compositions containing a compound of formula (I).
    一种抑制肿瘤转移的方法,其中向需要的受试者施用化合物(I)的有效量。还公开了一种治疗癌症的方法,其中向需要的受试者施用化疗药物的有效量和化合物(I)的有效量。此外,还公开了用于抑制肿瘤转移和治疗癌症的药物组合物,每种组合物均含有化合物(I)。
  • Carboxylic acid derivative and medicine comprising salt or ester of the same
    申请人:——
    公开号:US20040214888A1
    公开(公告)日:2004-10-28
    The present invention provides novel carboxylic acid derivatives useful as an insulin sensitizer, a salt thereof or a hydrate of them, and a medicament comprising the derivative as the active ingredient. Specifically, it provides a carboxylic acid derivative represented by the following formula: 1 (wherein L represents a single bond, or a C1 to C6 alkylene group, a C2 to C6 alkenylene group or a C2 to C6 alkynylene group, each of which may have one or more substituent groups; M represents a single bond, or a C1 to C6 alkylene group, a C2 to C6 alkenylene group or a C2 to C6 alkynylene group, each of which may have one or more substituent groups; T represents a single bond, or a C1 to C3 alkylene group, a C2 to C3 alkenylene group or a C2 to C3 alkynylene group, each of which may have one or more substituent groups; W represents a carboxyl group; X represents a single bond, an oxygen atom, or a group represented by the various substituent groups including —NR X1 CQ 1 O— (wherein Q 1 represents an oxygen atom or a sulfur atom; R X1 represents a hydrogen atom, a cyano group, a formyl group, or various groups including a C1 to C6 alkyl group and a C1 to C6 hydroxyalkyl group, each of which may have one or more substituent groups), ONR X1 CQ 1 —, —NR X1 CQ 1 —, —CQ 1 NR X1 —, —NR X1a CQ 1 NR X1b —, —Q 2 SO 2 — and —SO 2 Q 2 —; Y represents a 5 to 14-membered aromatic group which may have one or more substituent groups and one or more hetero atoms, or a C3 to C7 alicyclic hydrocarbon group; and the rings Z and U may be the same as or different from each other and each represents a 5 to 14-membered aromatic group which may have 1 to 4 substituent groups and one or more hetero atoms, and the ring may be partially saturated.), a salt thereof, an ester thereof or a hydrate of them.
    本发明提供了一种新型羧酸衍生物,可用作胰岛素增敏剂,其盐或其水合物,以及包含该衍生物作为活性成分的药物。具体而言,本发明提供了一种由以下式子表示的羧酸衍生物:1(其中L表示单键,或C1至C6烷基,C2至C6烯基或C2至C6炔基,每个基团都可以有一个或多个取代基;M表示单键,或C1至C6烷基,C2至C6烯基或C2至C6炔基,每个基团都可以有一个或多个取代基;T表示单键,或C1至C3烷基,C2至C3烯基或C2至C3炔基,每个基团都可以有一个或多个取代基;W表示羧基;X表示单键,氧原子,或由各种取代基表示的基团,包括-NRX1CQ1O-(其中Q1表示氧原子或硫原子;RX1表示氢原子,氰基,甲酰基或各种基团,包括C1至C6烷基和C1至C6羟基烷基,每个基团都可以有一个或多个取代基),ONRX1CQ1-,-NRX1CQ1-,-CQ1NRX1-,-NRX1aCQ1NRX1b-,-Q2SO2-和-SO2Q2-;Y表示一个具有1个或多个取代基和1个或多个杂原子的5至14环芳基,或一个C3至C7脂环烃基;环Z和环U可以相同或不同,每个环表示一个具有1至4个取代基和1个或多个杂原子的5至14环芳基,环可能部分饱和),其盐,酯或其水合物。
  • Benzisoxazole carboxylic acids
    申请人:Abbott Laboratories
    公开号:US04490384A1
    公开(公告)日:1984-12-25
    Described are compounds of the formula ##STR1## wherein X is hydrogen, loweralkyl, halo, loweralkoxy or trifluoromethyl, and Z is hydrogen, loweralkyl, halo, hydroxy or alkoxy, or compounds of the formula ##STR2## wherein X' and Y' may be the same or different and are selected from hydrogen, loweralkyl, or halo, and Z' is hydrogen, loweralkyl, halo, hydroxy or loweralkoxy, or pharmaceutically acceptable salts thereof. The compounds possess diuretic activity.
    描述了以下化合物的公式##STR1##其中X为氢、低烷基、卤素、低烷氧基或三氟甲基,Z为氢、低烷基、卤素、羟基或烷氧基,或者以下化合物的公式##STR2##其中X'和Y'可以相同也可以不同,选择自氢、低烷基或卤素,而Z'为氢、低烷基、卤素、羟基或低烷氧基,或其药学上可接受的盐。这些化合物具有利尿作用。
  • Pyrrolidine derivatives
    申请人:Pfizer Inc.
    公开号:US05233053A1
    公开(公告)日:1993-08-03
    Compounds of the formula ##STR1## wherein R, Y and R.sup.1 are as defined in the specification. These compounds are muscarinic receptor antagonists which are selective for smooth muscle muscarinic sites over cardiac muscarinic sites, and are useful in the treatment of diseases associated with altered motility on tone of smooth muscle, including irritable bowel syndrome, diverticular disease, urinary incontinence, oesophageal achalasia and chronic obstructive airways disease.
    式为##STR1##的化合物,其中R、Y和R.sup.1如规范中所定义。这些化合物是肌肉乙酰胆碱受体拮抗剂,对平滑肌乙酰胆碱受体位点选择性更高,而对心脏乙酰胆碱受体位点选择性较低,可用于治疗与平滑肌运动或张力改变有关的疾病,包括肠易激综合征、憩室病、尿失禁、食管无力症和慢性阻塞性呼吸道疾病。
查看更多